High Residual Activity of PMM2 in Patients’ Fibroblasts: Possible Pitfall in the Diagnosis of CDG-Ia (Phosphomannomutase Deficiency)  by Grünewald, Stephanie et al.
Am. J. Hum. Genet. 68:347–354, 2001
347
High Residual Activity of PMM2 in Patients’ Fibroblasts: Possible Pitfall
in the Diagnosis of CDG-Ia (Phosphomannomutase Deficiency)
Stephanie Gru¨newald,1 Els Schollen,1 Emile Van Schaftingen,3 Jaak Jaeken,2 and Gert Matthijs1
Centres for 1Human Genetics and 2Metabolic Disease, University of Leuven, Leuven; and 3Laboratory of Physiological Chemistry, Institute of
Cellular Pathology and University of Louvain, Brussels
Congenital disorders of glycosylation (CDGs) are a rapidly enlarging group of inherited diseases with abnormal
N-glycosylation of glycoconjugates. Most patients have CDG-Ia, which is due to a phosphomannomutase (PMM)
deficiency. In this article, we report that a significant portion (9 of 54) of patients with CDG-Ia had a rather high
residual PMM activity in fibroblasts included in the normal range (means of the controls 2 SD) and amounting
to 35%–70% of the mean control value. The clinical diagnosis of CDG-Ia was made difficult by the fact that most
(6 of 9) of these patients belong to a subgroup characterized by a phenotype that is milder than classical CDG-Ia.
These patients lack some of the symptoms that are suggestive for the diagnosis, such as inverted nipples and
abnormal fat deposition, and, as a mean, had higher residual PMM activities in fibroblasts ( mU/mg2.05 0.61
protein, ; vs. controls mU/mg protein, ), compared with patients with moderatenp 9 5.34 1.74 np 22
( mU/mg protein, ) or severe ( mU/mg protein, , ) cases. Yet they1.32 0.86 np 18 0.63 0.56 np 27 P ! .001
all showed mild mental retardation, hypotonia, cerebellar hypoplasia, and strabismus. All of them had an abnormal
serum transferrin pattern and a significantly reduced PMM activity in leukocytes. Six of the nine patients with mild
presentations were compound heterozygotes for the C241S mutation, which is known to reduce PMM activity by
only ∼2-fold. Our results indicate that intermediate PMM values in fibroblasts may mask the diagnosis of CDG-
Ia, which is better accomplished by measurement of PMM activity in leukocytes and mutation search in the PMM2
gene. They also indicate that there is some degree of correlation between the residual activity in fibroblasts and
the clinical phenotype.
Introduction
An estimated 300 patients worldwide are known to have
congenital disorders of glycosylation type Ia (CDG-Ia
[PMM deficiency, MIM 601785]), the most frequent
type among the CDGs (Van Schaftingen and Jaeken
1995; Jaeken et al. 1997a; Matthijs et al. 1997, 1999,
2000). Often patients can be diagnosed in the neonatal
or early infantile period on the basis of a typical mor-
phology (inverted nipples and fat pads), strabismus, ax-
ial hypotonia, and hyporeflexia. Recurrent elevated
transaminases and failure to thrive often complicate the
clinical course (Hagberg et al. 1993; Petersen et al. 1993;
Jaeken et al. 1997b). A very common feature is cerebellar
hypoplasia, which can be documented at or shortly after
birth (Jaeken and Carchon 1993; Akaboshi et al. 1995;
Jensen et al. 1995). There is a substantial childhood
mortality of ∼20%, due to severe infections or organ
failure (Hagberg et al. 1993; Petersen et al. 1993; Hutch-
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esson et al. 1995; Garcia Silva et al. 1996; van der Knaap
et al. 1996; Kristiansson et al. 1998; Matthijs et al.
2000).
At a later age, the impairment of the neurological
system becomes more evident, with a variable degree of
mental retardation, cerebellar dysfunction, and retinitis
pigmentosa (Andreasson et al. 1991; Fiumara et al.
1994; Di Rocco et al. 2000). Some children develop
seizures and/or strokelike episodes, probably because of
the particular coagulopathy with marked decrease of
factor XI, antithrombin, and proteins C and S (Oka-
moto et al. 1993; Van Geet and Jaeken 1993; Stibler et
al. 1996). In adulthood, nonprogressive ataxia, stable
mental retardation, and peripheral neuropathy are the
main characteristics of the disease (Stibler et al. 1994;
Barone et al. 1999). Most patients are wheelchair bound
(Stibler et al. 1994). Electrophysiological investigations
document decreased sensory and motor nerve–conduc-
tion velocities and abnormal somatosensory, auditory,
and visual evoked potentials (Itoh et al. 1993; Barone
et al. 1999). Adult female patients typically present with
hypergonadotropic hypogonadism (Ohzeki et al. 1993;
de Zegher and Jaeken 1995; Kristiansson et al. 1995).
The clinical suspicion of CDG can be substantiated
by isoelectric focusing (IEF) of serum transferrin (Jaeken
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Figure 1 Phosphomannomutase values measured in fibroblasts
of CDG-Ia patients ( ) and control subjects ( ). The meannp 54 np 22
value and SD ( mU/mg protein) in the control group is5.34 1.74
indicated. The scattered line gives the mean 2 SD (1.86 mU/mg
protein).
et al. 1984; Stibler and Jaeken 1990). Initially, IEF of
serum transferrin and PMM measurements in fibro-
blasts were performed mainly in patients presenting
with a “classical” and typically severe clinical picture
of CDG-Ia (Van Schaftingen and Jaeken 1995), and
often a profound PMM deficiency was documented
(Kjaergaard et al. 1998; Imtiaz et al. 2000). Thanks to
increasing awareness of CDGs and broader screening
for N-glycosylation defects, the number of patients with
a less typical presentation is growing, including children
with a much milder clinical presentation and nearly nor-
mal psychomotor development (Di Rocco et al. 2000;
van Ommen et al. 2000). Because we identified among
these cases patients with high residual PMM activity,
we decided to look for mutations in the PMM2 gene in
all patients who had a type 1 pattern in IEF and clinical
symptoms suggestive of CDG-Ia. The aims of the study
were to determine the percentage of patients with high
to normal residual PMM2 activity in fibroblasts and
to determine whether some cases could not be better
diagnosed by PMM assays in leukocytes rather than in
fibroblasts. After careful analysis of the clinical data, a
correlation between the severity of clinical expression
and residual PMM activity became apparent, to the ex-
tent that we have been able to identify the key symptoms
that best allow the identification of CDG-Ia (very mild
to severe cases) in patients. A comparison of the ge-
notype was made, to find out whether the high PMM
residual activities are typically associated with partic-
ular mutations.
Subjects and Methods
Subjects
Among 150 patients with a clinically suspected CDG
and a CDG type 1 pattern in serum transferrin IEF, the
diagnosis of CDG-Ia was confirmed in 50 patients by
identification of PMM deficiency in fibroblasts and by
mutation analysis. In the remaining patients, the clinical
data were reviewed and 14 patients with a clinical pic-
ture compatible with CDG-Ia were identified. In spite of
PMM activities in fibroblasts within the normal range
in four of these patients, the diagnosis was confirmed
by the identification of PMM2 mutations. Thus, a total
of 54 patients were included in this study. Clinical data
were collected via a questionnaire (including family and
patient history, biochemical data, and clinical symp-
toms), by literature review, and through personal com-
munication. In addition, PMM values were measured in
patients’ and parents’ leukocytes, if available.
Isoelectrofocusing of Serum Transferrin
Analysis of transferrin isoforms was performed in se-
rum and dried blood spots by IEF as described elsewhere
(Stibler and Cederberg 1993; de Jong et al. 1994).
PMM Measurement in Fibroblasts and Leukocytes
PMM was measured in fibroblasts and leukocytes as
described elsewhere (Jaeken et al. 1997a). The means of
the three groups were compared by ANOVA analysis,
followed by a post hoc test for pairwise comparison,
using the Bonferroni correction for multiple testing.
Mutation Studies
Genomic DNA was isolated from fibroblasts or white
blood cells by means of standard laboratory procedures.
Mutations were identified by a combination of SSCP
analysis and direct sequencing, as described elsewhere
(Matthijs et al. 1998b).
Results
Figure 1 shows the PMM values in fibroblasts from 54
patients with CDG-Ia and from 22 control subjects.
There is obviously a wide scatter of values in both
groups, with overlap. If the mean control value (5.34
mU/mg protein)  2 SD ( mU/mg protein) is2# 1.74
taken to define the normal range, CDG-Ia would not
have been diagnosed in as many as 9 of 54 patients. In
four cases the PMM values were 35%, 41%, 62%, and
70% of the mean control value, clearly within the nor-
mal range. These patients received diagnoses only when
we decided to search for mutations in patients with high
PMM values.
Figure 2 shows the values of the PMM activities in
leukocytes. There is no overlap between the values for
the control subjects and for patients with CDG-Ia. In
particular, the patients with high residual activities in
fibroblasts displayed activities in leukocytes that were
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Figure 2 Phosphomannomutase values measured in leukocytes
of patients with CDG-Ia ( ), heterozygotes ( ), and controlnp 37 np 38
subjects ( ). The mean value and standard deviation (SD)np 19
( mU/mg protein) in the control group is indicated. The2.19 0.57
scattered line reflects the mean 2 SD (1.05 mU/mg protein).
in the range of 0.01–0.32 mU/mg protein (13 SD below
the mean control value) (see table 1). Figure 2 also
shows the distribution of the values of the obligate het-
erozygotes (parents of CDG-Ia patients). Although there
is an overlap with the controls, 72% of the values are
12 SD below the mean control value.
Table 1 lists the residual PMM activities in fibroblasts
from the CDG-Ia patients included in this study (in mU/
mg protein; the corresponding leukocyte values are
given when available). In an attempt to characterize the
variable phenotype of the CDG-Ia patients, the clinical
outcome was graded as mild, moderate, or severe on
the basis of the predominant clinical symptoms. Patients
with the classical CDG-Ia phenotype, including failure
to thrive, recurrent infections, multiorgan involvement,
convulsions, retinitis pigmentosa, severe developmental
delay and inability to walk, peripheral neuropathy, or
scoliosis were classified as having “severe” clinical ex-
pression. This group includes the patients who died
early in childhood. Patients with mild developmental
delay but who learned to sit and walk and had no failure
to thrive, no feeding difficulties, no visceral organ prob-
lems, or no disturbance of clotting factors and trans-
aminases were classified as having “mild” clinical ex-
pression. Between these extremes were the patients with
“moderate” clinical expression. In all patients, psycho-
motor retardation (to a very variable degree), strabis-
mus, hypotonia, and cerebellar hypoplasia were docu-
mented. There is a clear overrepresentation of (very)
mild cases in the group with residual PMM activities
125% of normal, measured in fibroblasts. Overall, there
is a correlation between the severity of clinical presen-
tation and the decrease of PMM activity in fibroblasts:
in the 9 patients with mild expression, mU/2.05 0.61
mg protein PMM activity was measured; in the 18 pa-
tients with moderate expression, mU/mg1.32 0.86
protein; and in the 27 severely affected patients,
mU/mg protein ( for a comparison0.63 0.56 P ! .001
of the means of the three groups; P values for compar-
isons of mild vs. moderate, moderate vs. severe, and
mild vs. severe are .034, .004, and !.001, respectively)
(control subjects 5.34  1.74 mU/mg protein; np
).22
Table 2 summarizes the frequency of typical symp-
toms in the general CDG-Ia population and compares
it with the occurrence of these symptoms in the group
of patients with mild cases of CDG (as available to the
authors). Remarkably, inverted nipples, fat pads, failure
to thrive, and convulsions are absent in the latter group.
On the other hand, all patients present with strabismus,
hypotonia, cerebellar hypoplasia, and mental retarda-
tion, although to a very variable degree.
Table 1 also lists the mutation data for the CDG-Ia
patients included in this study, which allows for a com-
parison between the phenotype, the PMM activity, and
the genotype. Among the plethora of missense muta-
tions observed in this group, several mutations are more
frequent. First, the common R141H mutation is ob-
served in 33 of 54 cases. Second, two mutations are
frequently associated with the milder phenotype. Mu-
tation C241S in combination with R141H or with
F157S was found only in patients with relatively high
residual PMM activity and a (very) mild clinical picture.
Mutation T237M, again in combination with R141H,
is also more frequently found among the patients with
higher residual activity, whereas, in the patients with
low residual activity, it is found in combination with
P113L and T237R. On the other hand, the phenotype
in six of seven patients who are compound heterozygous
for V231M and R141H was severe. One child died in
early childhood because of liver failure. Finally, patients
who are compound heterozygous for F119L andR141H
are found only in the CDG-Ia patient group with a low
residual activity of PMM in fibroblasts, and all patients
were severely affected. One patient homozygous for
F119L had a more favorable clinical outcome. The clin-
ical presentation in five pairs of siblings was only
slightly different. The PMM activities were in the same
range but not necessarily in direct relation to the severity
of the disease (e.g., in patients 18 and 7).
Discussion
CDG-Ia occurs worldwide, and patients can presentwith
a wide range of symptoms. By using IEF of serum trans-
ferrin as a screening test for N-glycosylation defects, we
have found several patients with an abnormal pattern
that did not present the full diagnostic criteria for CDG-
Ia. Enzyme analysis showed, in many of these patients,
a PMM deficiency, establishing the diagnosis of CDG-
Table 1
Characteristics of 54 Patients with CDG-Ia
Patient
Number,a Sex Genotype
PMM in Fibroblasts
(mU/mg protein) Passageb
PMM in Leukocytes
(mU/mg protein) Phenotype
5, F R141H/C241S 2.19 (4) .32 Very mildc
8, F R141H/C241S 2.1 3 (3) .22 Very mild
181, M R141H/C241S 1.41 (3) .22 Very mildd
2, M L32R/R141H 3.35 (2) .20 Mild
4, M R123Q/T226S 2.36 5 (5) .28 Mild
71, M R141H/C241S 2.15 (3) .16 Mild
92, M F157S/C241S 1.88 6 (2) .13 Mild
142, F F157S/C241S 1.62 (1) .24 Mild
20, F R141H/T237M 1.35 4 (4) .14 Mild
33, F R239W/F157S 2.8 9 (6) .08 Mild–moderate
11, F R141H/T237M 1.68 (3) … Mild–moderate
21, M R141H/T237M 1.34 (4) .19 Mild–moderate
26, F R141H/H195R .94 (2) … Mild–moderate
37, M E151G/R141H .54 (2) … Mild–moderate
1, M R141H/R162W 3.75 (3) … Moderate
133, F R239W/F157S 1.65 7 (5) .07 Moderate
16, F R141H/E197A 1.49 4 (4) .23 Moderate
17, F R141H/T237M 1.45 4 (4) .31 Moderate
19, F R141H/D65Y 1.38 (2) … Moderate
23, M R141H/V231M 1.25 (3) .27 Moderate
28, M N216I/N216I .9 5 (5) .14 Moderate
31, M P113L/F157S .77 (5) .10 Moderate
33, F D65Y/D65Y .64 4 (4) … Moderate
40, M I132T/R141H .41 (3) … Moderate
51, M F119L/F119L .13 (3) … Moderate
15, F F157S/T237M 1.52 4 (4) … Moderate–severe
24, M IVS32CrT/H218L 1.03 (3) .00 Moderate–severe
6, M R123Q/I153T 2.19 (3) .01 Severee
10, M V44A/R123Q 1.8 (3) … Severe
254, F R141H/V231M .98 (3) … Severe
29, F R141H/V231M .9 (3) … Severe
32, M R141H/V231M .64 (3) .02 Severe
34, F P69S/R141H .6 (3) … Severe
36, M V44A/R141H .57 (3) .42 Severe
38, M F119L/R141H .49 6 (6) … Severe
395, F P113L/T237M .43 (2) … Severe
41, M R141H/V231M .33 (3) … Severe
42, M P113L/R141H .32 (3) … Severe
44, F R141H/T237M .28 5 (5) … Severe
454, F R141H/V231M .27 (4) … Severe
46, F F119L/R141H .26 (4) … Severe
475, F P113L/T237M .19 (2) … Severe
48, F D188G/R141H .17 7 (7) … Severe
49, M F119L/R141H .17 (3) … Severe
50, F F119L/R141H .14 (4) … Severe
52, F P113L/R123Q .09 (4) … Severe
53, F T237M/T237R A233Tf .04 (0) … Severe
12, M Y76C/F206T 1.67 (4) … Severeg
22, F V129M/IVS32CrT 1.25 (4) … Severeh
27, F D65Y/R123Q .91 (2) … Severeh
30, M R141H/D65Y .81 (3) … Severeh
35, M D65Y/F157S .57 (3) … Severeh
43, F R141H/V231M .3 5 (5) … Severeh
54, F D188G/R141H .02 7 (7) … Severeh
NOTE.—Patients with CDG-Ia were listed according to the clinical presentation but numbered according to the residual activity
measured in fibroblasts. Definitions of “mild,” “moderate,” and “severe” are given in the Results section.
a Patients were numbered according to the residual PMM activity in fibroblasts (patient 1 had the highest activity; patient 54
had the lowest activity). Sib pairs are indicated by superscript numbers.
b The total passage number is given if known; the number of passages between arrival in the cell culture facility in Leuven
and the enzymatic measurements is given in parentheses.
c Patient attends normal school.
d Estimated full-scale IQ: 80.
e Child of a drug addict.
f This patient has A233T on the same allele as T237R.
g Premature at 32 gestational weeks; died at age 13 years.
h Died during the first year of life.
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Table 2
Frequency of Reported Clinical Symptoms in All CDG-Ia Cases in
This Series and in the Cases Considered “Mild”
Clinical and Biochemical Features All Cases (%) Mild Cases (%)
Inverted nipples 10/26 (38) 0/9 (0)
Fat pads 10/26 (38) 0/9 (0)
Failure to thrive 13/30 (43) 0/9 (0)
Elevated transaminases 13/25 (52) 0/9 (0)
Clotting factor deficiency 17/23 (75) 2/9 (22)
Convulsions or strokes 10/27 (37) 0/9 (0)
Strabismus 33/33 (100) 9/9 (100)
Hypotonia 33/33 (100) 9/9 (100)
Cerebellar hypoplasia 33/33 (100) 9/9 (100)
Mental retardation 33/33 (100) 9/9 (100)
NOTE.—Data are no. of cases with characteristic/total no. of cases
for which data are available.
Ia. Since high PMM activities (up to 25% of the normal
activity) had been reported in fibroblasts or lympho-
blasts from some patients (Matthijs et al. 1998b), mu-
tation search in the PMM2 gene was also performed in
patients with fibroblast PMM values in the normal
range, leading to the diagnosis of additional CDG-Ia
cases. Thus, the data presented in this study show that
the residual PMM activities in fibroblasts from patients
with two allelic mutations in the PMM2 gene could be
quite high, reaching 70% of the normal value in one
patient. The problem with partial deficiencies has not
been encountered in assays performed in leukocytes.
Thus, in patients with high residual PMM activity in
fibroblasts, analysis of PMM activity in leukocytes can
substantiate the diagnosis of CDG-Ia.
The difference between the residual activity in fibro-
blasts and in leukocytes points to a cell-specific effect.
Analysis of the mutant proteins in vitro has shown that
they have altered kinetic properties, with Vmax values
ranging from 0.4% to ∼50% of the wild-type enzyme,
and that they are less stable than the latter (Kjaergaard
et al. 1999; Pirard et al. 1999; Vuillaumier-Barrot et al.
2000). This difference in stability is most likely respon-
sible for the fact that the residual activities are, as a
rule, higher in fibroblasts, which are rapidly dividing
cells with active protein synthesis, than in leukocytes,
most of which are terminally differentiated cells with
little or no protein synthesis. This problem may be com-
pounded by the fact that a higher PMM2 residual ac-
tivity may lead to a selective advantage in culture con-
dition and to overgrowth. In this way, the passage
number of the cells may affect the PMM values. How-
ever, there is no apparent influence of passage number
on the PMM values (see table 1), although it was not
possible to retrieve the passage number for all fibroblast
cultures. Alternatively, the growth phase of the cells
might affect the measurement, although this is unlikely
for the fibroblasts, because they were all grown to
confluency.
Measurement of PMM activity in leukocytes of ob-
ligate carriers showed that this enzyme activity was be-
low the mean value 2 SD in 70% of the cases. Thus,
PMM assays in leukocytes were also useful for the iden-
tification of carriers. In practice, when no material is
left from the proband, indirect evidence can be obtained
from the PMM activities in leukocytes of the parents
(Matthijs et al. 1998a).
It is obvious that hypotonia, strabismus, cerebellar
hypoplasia, and mental retardation are consistent fea-
tures in CDG-Ia and are therefore reliable diagnostic
criteria, whereas convulsions and/or strokelike events
and visceral complications are less common in the
milder cases. Importantly, typical symptoms such as in-
verted nipples, abnormal fat pad distribution, and fail-
ure to thrive are missing in these patients.
The PMM2 protein is encoded by the PMM2 gene,
located on chromosome 16p13 (Matthijs et al. 1997).
The open reading frame of 738 nucleotides predicts a
protein of 246 amino acids, whose three-dimensional
structure is not yet known. PMM2 belongs to the halo-
acid dehalogenase superfamily of proteins, which are
characterized by the conservation of three different mo-
tifs that are most likely involved in the catalytic activity
(fig. 3) (Aravind et al. 1998). The reaction mechanism
of the enzyme involves the phosphorylation of the first
aspartate in an extremely conserved DXDXT/V se-
quence that is close to the amino-terminus of the enzyme
(Asp-12; see fig. 3) and is also found in a series of other
phosphatases and phosphomutases (Collet et al. 1998).
Mutation analysis in CDG-Ia patients reveals a pleth-
ora of mutations, mainly missense (Matthijs et al. 1997,
1998b, 2000; Kjaergaard et al. 1998; Bjursell et al.
2000; Imtiaz et al. 2000; de Lonlay et al. 2001). R141H,
the most frequent mutation among whites, is present in
33 of 54 cases in this series, and this frequency does
not differ from the overall frequency of this mutation
among patients described elsewhere (Congenital Dis-
orders of Glycosylation Web site). However, R141H is
a severe mutation with virtually no residual activity, as
shown by overexpression of the mutant protein (Kjaer-
gaard et al. 1999; Pirard et al. 1999), which might ex-
plain why homozygosity for this mutation has not been
observed (Kjaergaard et al. 1998; Matthijs et al. 1998b;
Schollen et al. 2000). Thus, whenever the R141H mu-
tation is found in patients, differences in the clinical
presentation and in the residual activity in fibroblasts
are likely to correlate with the mutations in the second
allele.
In this series, one mutation—C241S—is particularly
frequent in the milder phenotypes (see table 1). The
C241S mutation is in the C-terminal part of the protein,
in a nonconserved region, and seems to impair the pro-
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Figure 3 Nucleotide and amino acid sequence of PMM2. Amino
acid residues that are phylogenetically strictly conserved are indicated
in boldface type. The mutations that are discussed in the context of
this study are indicated. Amino acid 241 is not conserved at all,
whereas amino acid 237 is conserved between human and yeast but
not between human/yeast and Babesia bovis (see also Matthijs et al.
2000). On the basis of structural data obtained with P-type ATPases,
Aravind et al. (1998) have delineated three motifs, in the phospho-
mannomutases, that may be directly involved in the catalytic activity.
They are underlined.
tein activity to a minor extent, since it decreases the
activity by only 50% (Vuillaumier-Barrot et al. 2000).
The combination of R141H/T237M is also observed
more frequently in the patients with higher residual ac-
tivity in fibroblasts, but the phenotype ranges frommild
to severe. T237M affects a conserved amino acid of the
protein, and one can assume that the mutated protein
has only limited residual activity. When T237M is com-
bined with either P113L, T237R or F157S, the clinical
outcome is severe. Because the enzyme acts as a
(homo)dimer, the differences between the effects of these
combinations of mutations might be due to molecular
“interactions” between the mutated proteins.
V231M is also frequent in the group of patients de-
scribed here. The V231M mutation has a residual ac-
tivity of 38.5%, but the mutated protein is extremely
unstable (Pirard et al. 1999), which might explain why
the compound heterozygous patients with R141H/
V231M have, in general, a less favorable clinical out-
come than patients with the R141H/C241S mutation.
F119L is the second most common PMM2 mutation in
CDG-Ia, because of a founder effect in the Scandinavian
population (Bjursell et al. 1997; Kjaergaard et al. 1998).
Its presence among the CDG-Ia patients in this series
who are heterozygous for F119L/R141H was limited to
severe cases. In expression studies of F119L in Escher-
ichia coli, a residual activity of 25% was measured and
the mutated protein showed a marked decrease of sub-
strate affinity (Kjaergaard et al. 1999; Pirard et al.
1999). The other mutations are too rare for conclusions
about their phenotypic impact to be drawn.
In conclusion, patients with high to normal residual
activity of PMM in fibroblasts may harbor mutations
in PMM2.Most of these patients have mild to moderate
clinical expression, significantly broadening the spec-
trum of CDG-Ia.
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